SG10202113198TA - Dementia therapeutic agent combining pyrazoloquinoline derivative and donepezil - Google Patents
Dementia therapeutic agent combining pyrazoloquinoline derivative and donepezilInfo
- Publication number
- SG10202113198TA SG10202113198TA SG10202113198TA SG10202113198TA SG10202113198TA SG 10202113198T A SG10202113198T A SG 10202113198TA SG 10202113198T A SG10202113198T A SG 10202113198TA SG 10202113198T A SG10202113198T A SG 10202113198TA SG 10202113198T A SG10202113198T A SG 10202113198TA
- Authority
- SG
- Singapore
- Prior art keywords
- donepezil
- therapeutic agent
- agent combining
- dementia therapeutic
- pyrazoloquinoline derivative
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762513692P | 2017-06-01 | 2017-06-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10202113198TA true SG10202113198TA (en) | 2021-12-30 |
Family
ID=64455958
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202113198TA SG10202113198TA (en) | 2017-06-01 | 2018-05-30 | Dementia therapeutic agent combining pyrazoloquinoline derivative and donepezil |
| SG11201909595V SG11201909595VA (en) | 2017-06-01 | 2018-05-30 | Dementia therapeutic agent combining pyrazoloquinoline derivative and donepezil |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201909595V SG11201909595VA (en) | 2017-06-01 | 2018-05-30 | Dementia therapeutic agent combining pyrazoloquinoline derivative and donepezil |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11833146B2 (en) |
| EP (1) | EP3632439B1 (en) |
| JP (2) | JP7079777B2 (en) |
| KR (1) | KR102627787B1 (en) |
| CN (1) | CN110603040B (en) |
| AU (1) | AU2018276565A1 (en) |
| BR (1) | BR112019023569A2 (en) |
| CA (1) | CA3060030A1 (en) |
| IL (1) | IL270395B (en) |
| RU (1) | RU2019135834A (en) |
| SG (2) | SG10202113198TA (en) |
| WO (1) | WO2018221545A1 (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110603039B (en) | 2017-06-01 | 2023-02-28 | 卫材R&D管理有限公司 | Dementia therapeutic agent combining pyrazoloquinoline derivative and memantine |
| WO2018221551A1 (en) | 2017-06-01 | 2018-12-06 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Lewy body disease therapeutic agent containing pyrazoloquinoline derivative |
| RU2019135261A (en) | 2017-06-01 | 2021-07-09 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | PHARMACEUTICAL COMPOSITION CONTAINING PDE9 INHIBITOR |
| KR102271305B1 (en) | 2020-05-21 | 2021-06-30 | 주식회사 아리바이오 | Composition for preventing and treating dementia |
| KR102272907B1 (en) | 2020-11-05 | 2021-07-05 | 주식회사 아리바이오 | Composition for preventing and treating dementia |
| KR102272910B1 (en) | 2021-01-28 | 2021-07-06 | 주식회사 아리바이오 | Composition for prevention and treating dementia with diabetes |
| KR20220140960A (en) | 2021-04-12 | 2022-10-19 | 주식회사 아리바이오 | Composition for prevention and treating dementia with diabetes |
| KR102311224B1 (en) * | 2021-04-23 | 2021-10-13 | 주식회사 아리바이오 | Composition for prevention and treating dementia through the combination of PDE5 inhibitors and glucocorticoid receptor antagonists |
| KR20220146095A (en) | 2021-04-23 | 2022-11-01 | 주식회사 아리바이오 | Composition for prevention and treating dementia through the combination of PDE5 inhibitors and glucocorticoid receptor antagonists |
| US11939328B2 (en) | 2021-10-14 | 2024-03-26 | Incyte Corporation | Quinoline compounds as inhibitors of KRAS |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05132484A (en) | 1991-04-26 | 1993-05-28 | Otsuka Pharmaceut Factory Inc | Pyrazoloquinoline and pyrazolonaphthylidene derivative |
| CA2189776A1 (en) | 1994-05-24 | 1995-11-30 | Bernd Buttelmann | Tricyclic dicarbonyl derivatives |
| GB9612710D0 (en) * | 1996-06-18 | 1996-08-21 | Pfizer Ltd | Method of treatment |
| AU5716898A (en) * | 1997-01-08 | 1998-08-03 | Warner-Lambert Company | Acetylcholinesterase inhibitors in combination with muscarinic agonists for the treatment of alzheimer's disease |
| US5962535A (en) * | 1997-01-17 | 1999-10-05 | Takeda Chemical Industries, Ltd. | Composition for alzheimer's disease |
| HN2002000317A (en) | 2001-11-02 | 2003-05-21 | Pfizer | PDE9 INHIBITORS FOR TREATMENT OF CARDIOVASCULAR DISORDERS |
| AU2003250539A1 (en) | 2002-08-07 | 2004-02-25 | Mitsubishi Pharma Corporation | Dihydropyrazolopyridine compounds |
| DE10238722A1 (en) | 2002-08-23 | 2004-03-11 | Bayer Ag | Improving attention, concentration, cognition, learning and/or memory performance, using selective phosphodiesterase 9A inhibitors, preferably 4H-pyrazolo-(3,4-d)-pyrimidin-4-one derivatives |
| DE102004004142A1 (en) | 2003-05-09 | 2004-11-25 | Bayer Healthcare Ag | 6-Cyclylmethyl- and 6-alkylmethyl-substituted pyrazolopyrimidines |
| RU2426734C2 (en) | 2003-10-03 | 2011-08-20 | Зм Инновейтив Пропертиз Компани | Pyrazolopyridines and analogues thereof |
| WO2005118583A1 (en) | 2004-05-28 | 2005-12-15 | Millennium Pharmaceuticals, Inc. | 2, 5-dihydro-pyrazolo`4, 3-c!quinolin-4-ones as chk-1 inhibitors |
| JP2006045118A (en) | 2004-08-04 | 2006-02-16 | Mochida Pharmaceut Co Ltd | New pyrazoloquinolone derivative |
| AU2006289838B2 (en) | 2005-09-15 | 2011-08-18 | Aska Pharmaceutical Co., Ltd. | Heterocyclic compound, and production process and use thereof |
| CA2672591A1 (en) | 2006-12-13 | 2008-06-19 | Aska Pharmaceutical Co., Ltd. | Treating agent of uropathy |
| KR101563103B1 (en) | 2006-12-13 | 2015-10-23 | 아스카 세이야쿠 가부시키가이샤 | Quinoxaline derivative |
| GEP20125405B (en) | 2007-05-11 | 2012-02-27 | Pfizer | Amino-heterocyclic compounds |
| UA105362C2 (en) | 2008-04-02 | 2014-05-12 | Бьорингер Ингельхайм Интернациональ Гмбх | 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators |
| WO2010026214A1 (en) | 2008-09-08 | 2010-03-11 | Boehringer Ingelheim International Gmbh | Pyrazolopyrimidines and their use for the treatment of cns disorders |
| TWI404721B (en) * | 2009-01-26 | 2013-08-11 | Pfizer | Amino-heterocyclic compounds |
| US8357688B2 (en) | 2009-03-05 | 2013-01-22 | Astellas Pharma Inc. | Substituted imidazo[1,5-a]quinoxalin-4(5H)-ones as PDE9 inhibitors |
| PL2414363T3 (en) | 2009-03-31 | 2014-06-30 | Boehringer Ingelheim Int | 1-heterocyclyl-1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-one derivatives and their use as pde9a modulators |
| US8880976B2 (en) | 2009-09-25 | 2014-11-04 | Stmicroelectronics, Inc. | Method and apparatus for encoding LBA information into the parity of a LDPC system |
| UA110347C2 (en) | 2010-08-12 | 2015-12-25 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Derivative 6-cycloalkanes 1.5 dyhidropirazol [3,4-d] pyrimidine-4-one and their use as inhibitors pde9a |
| CN103097383B (en) | 2010-09-07 | 2015-09-16 | 安斯泰来制药株式会社 | Pyrazoloquinoline compound |
| US20130040971A1 (en) | 2011-02-14 | 2013-02-14 | Boehringer Ingelheim International Gmbh | 6-cycloalkyl-pyrazolopyrimidinones for the treatment of cns disorders |
| US8809345B2 (en) | 2011-02-15 | 2014-08-19 | Boehringer Ingelheim International Gmbh | 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders |
| JP2013051639A (en) | 2011-08-31 | 2013-03-14 | Kyocera Document Solutions Inc | Image formation means |
| PL2573073T3 (en) | 2011-09-26 | 2015-04-30 | Sanofi Sa | Pyrazoloquinolinone derivatives, preparation thereof and therapeutic use thereof |
| JP6042060B2 (en) | 2011-09-26 | 2016-12-14 | サノフイ | Pyrazoloquinolinone derivatives, their preparation and therapeutic use |
| AU2012319549B2 (en) | 2011-10-07 | 2016-07-28 | Eisai R&D Management Co., Ltd. | Pyrazoloquinoline derivative |
| CA2907971C (en) * | 2013-04-05 | 2020-12-29 | Eisai R&D Management Co., Ltd. | Salt of pyrazoloquinoline derivative, and crystal thereof |
| CN110603039B (en) | 2017-06-01 | 2023-02-28 | 卫材R&D管理有限公司 | Dementia therapeutic agent combining pyrazoloquinoline derivative and memantine |
| RU2019135261A (en) | 2017-06-01 | 2021-07-09 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | PHARMACEUTICAL COMPOSITION CONTAINING PDE9 INHIBITOR |
| WO2018221551A1 (en) | 2017-06-01 | 2018-12-06 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Lewy body disease therapeutic agent containing pyrazoloquinoline derivative |
| CN108563565B (en) | 2018-04-08 | 2021-12-17 | 中国人民解放军海军工程大学 | Method for establishing reliability quantitative analysis model of flight landing guidance system |
-
2018
- 2018-05-30 CN CN201880030220.5A patent/CN110603040B/en active Active
- 2018-05-30 SG SG10202113198TA patent/SG10202113198TA/en unknown
- 2018-05-30 JP JP2019521248A patent/JP7079777B2/en active Active
- 2018-05-30 AU AU2018276565A patent/AU2018276565A1/en active Pending
- 2018-05-30 SG SG11201909595V patent/SG11201909595VA/en unknown
- 2018-05-30 EP EP18810578.7A patent/EP3632439B1/en active Active
- 2018-05-30 CA CA3060030A patent/CA3060030A1/en active Pending
- 2018-05-30 US US16/607,402 patent/US11833146B2/en active Active
- 2018-05-30 KR KR1020197033197A patent/KR102627787B1/en active IP Right Grant
- 2018-05-30 RU RU2019135834A patent/RU2019135834A/en unknown
- 2018-05-30 WO PCT/JP2018/020638 patent/WO2018221545A1/en active Application Filing
- 2018-05-30 BR BR112019023569-8A patent/BR112019023569A2/en active Search and Examination
- 2018-05-30 IL IL270395A patent/IL270395B/en unknown
-
2022
- 2022-05-23 JP JP2022083947A patent/JP7288999B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| RU2019135834A3 (en) | 2021-10-15 |
| EP3632439A4 (en) | 2021-02-17 |
| SG11201909595VA (en) | 2019-11-28 |
| IL270395A (en) | 2020-02-27 |
| RU2019135834A (en) | 2021-07-13 |
| CN110603040B (en) | 2023-02-28 |
| AU2018276565A1 (en) | 2019-11-07 |
| JP7288999B2 (en) | 2023-06-08 |
| CA3060030A1 (en) | 2018-12-06 |
| EP3632439A1 (en) | 2020-04-08 |
| BR112019023569A2 (en) | 2020-06-02 |
| WO2018221545A1 (en) | 2018-12-06 |
| CN110603040A (en) | 2019-12-20 |
| US11833146B2 (en) | 2023-12-05 |
| KR102627787B1 (en) | 2024-01-23 |
| JPWO2018221545A1 (en) | 2020-04-02 |
| JP2022110143A (en) | 2022-07-28 |
| EP3632439B1 (en) | 2024-03-27 |
| JP7079777B2 (en) | 2022-06-02 |
| US20200129501A1 (en) | 2020-04-30 |
| KR20200010224A (en) | 2020-01-30 |
| IL270395B (en) | 2022-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10202113198TA (en) | Dementia therapeutic agent combining pyrazoloquinoline derivative and donepezil | |
| IL262470B (en) | Isoquinoline-3 carboxamide derivatives and pharmaceutical compositions comprising them | |
| IL275600A (en) | Exosomes for immuno-oncology and anti-inflammatory therapy | |
| HK1259145A1 (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
| IL273664A (en) | Fill-finish assemblies and related methods | |
| ZA201805805B (en) | Formulations and methods | |
| SG10202113199RA (en) | Dementia therapeutic agent combining pyrazoloquinoline derivative and memantine | |
| PL3558280T3 (en) | Migraine prevention and treatment | |
| EP3534910A4 (en) | Therapeutic agents and methods | |
| IL255530A (en) | Efflux-pump inhibitors and therapeutic uses thereof | |
| IL264167A (en) | Compositions and methods for treating frontotemporal dementia | |
| GB201711234D0 (en) | Pyrrolopyrimidine and pyrrolopyridine derivatives | |
| GB201710288D0 (en) | Products and methods | |
| IL266132B (en) | Pharmaceutical formulations and methods of making the same | |
| PL3565374T3 (en) | Region configuration methods and devices | |
| IL271327A (en) | Compositions and methods for enhancing hyperthermia therapy | |
| IL270011B (en) | Therapeutic compounds and methods | |
| IL264977A (en) | Methods and compositions for the treatment of melanoma | |
| EP3701956A4 (en) | Prophylactic and/or therapeutic agent for dementia | |
| ZA202000959B (en) | Adamantylmethylamine derivative and use thereof as pharmaceutical | |
| GB201519644D0 (en) | Therapy and pharmaceutical composition | |
| GB201700635D0 (en) | Barrier-controlling sanitising apparatus and methods | |
| PL3302473T3 (en) | Preparation of sufentanil citrate and sufentanil base | |
| IL282671A (en) | Therapeutic methods and compositions | |
| GB2562322B (en) | Furniture unit and method of use thereof |